Lotte Biologics kicks off ADC service at Syracuse plant
Lotte Biologics announced on Thursday that it has signed a manufacturing deal with a biotech firm based in Asia to produce a clinical-stage antibody-drug conjugate candidate.
The deal represents the first major milestone in launching full-scale operations at the company's ADC manufacturing facility, located at the Syracuse Bio Campus in the US state of New York, an expansion project that began in 2023.
Through the contract, Lotte Biologics is officially introducing its ADC contract development and manufacturing services, tailored to support clients across all stages, from clinical trials to commercial-scale production.
"With this contract as a starting point, we will ensure a stable supply of high-quality ADC therapeutics and solidify our position in the global market, not only as an antibody manufacturer, but also as a CDMO specializing in ADCs,' Lotte Biologics CEO James Park said. 'We also plan to actively pursue partnerships to further strengthen our competitiveness in the ADC modality business."
Lotte Biologics will continue to seek new clients and expand its collaborative efforts, aiming to provide integrated, one-stop solutions for ADC development and production, the firm said.
Developed with an investment of around $100 million, Lotte Biologics' ADC facility meets the current Good Manufacturing Practices of the US Food and Drug Administration and delivers comprehensive end-to-end manufacturing services.
The facility includes a fully integrated production and purification system, featuring a conjugation reactor capable of handling up to 1,000 liters. It also offers in-house quality control testing and advanced analytical characterization services.
Additionally, the site is outfitted with a single-use system that supports the entire workflow — from antibody preprocessing to the automated aseptic filling of drug substances — allowing for flexible and efficient service tailored to diverse client requirements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
![[Bio USA] Lotte heir deepens global biotech outreach at Bio USA](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F17%2Fnews-p.v1.20250617.5d83ef2cc2dc48378e5a284a0e7e1c62_T1.jpg&w=3840&q=100)
![[Bio USA] Lotte heir deepens global biotech outreach at Bio USA](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75){kind=small}
Korea Herald
2 days ago
- Korea Herald
[Bio USA] Lotte heir deepens global biotech outreach at Bio USA
BOSTON -- Shin Yoo-yeol, head of global strategy at Lotte Biologics and the eldest son of Lotte Group Chairman Shin Dong-bin, was seen engaging with industry players at the 2025 BIO International Convention in Boston on Monday. While most of the practical discussions at exhibitor booths were led by Lotte Biologics CEO James Park, who accompanied the younger Shin throughout the event, Shin was seen listening attentively to key business updates, exchanging business cards with booth representatives and showing genuine interest in the conversations. 'This is my second time attending the Bio USA, and I have high expectations for this year," Shin told reporters at the venue. 'I plan to attend several key meetings with global companies throughout the period.' Shin's booth tour included Korean and international names, such as Dong-A ST, Celltrion, Dr. Reddy's Biologics, Thermo Fisher Scientific and SK Pharmteco, reflecting his broad interest in potential partners and future collaboration. 'While there's a predetermined list of booths to visit, Shin also adds companies he finds interesting on the spot,' said a Lotte Biologics official. At the Dong-A ST booth, with Shin present, ST Pharm CEO Sung Moo-jae and Lotte Biologics CEO exchanged questions regarding antibody-drug conjugate (ADC) development, and discussed the potential for future business cooperation. Earlier this year in January, Shin made an appearance at the JPMorgan Healthcare Conference in San Francisco, where other second- and third-generation conglomerate leaders, including Celltrion's Seo Jin-seok and SK Biopharmaceuticals' Chey Yoon-chung also attended. At the time, Shin's participation followed a visit to CES 2025 in Las Vegas. This time, he is believed to have arrived at Bio USA after participating in the 2025 Consumer Goods Forum Global Summit, held June 10–13 in Amsterdam, Netherlands.
![[Bio USA] Samsung, Celltrion, SK lead Korea's largest showing at Bio USA 2025](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F17%2Fnews-p.v1.20250617.2bee40b011f44218bc173159e122bcf0_T1.jpg&w=3840&q=100)
Korea Herald
2 days ago
- Korea Herald
[Bio USA] Samsung, Celltrion, SK lead Korea's largest showing at Bio USA 2025
Korean biotech firms court global deals with ADC, organoids, Alzheimer's focus BOSTON — South Korean biotech companies are making a strong showing at the BIO International Convention 2025, which kicked off Monday in Boston for a four-day run. Widely regarded as the world's largest and most influential biotechnology exhibition, this year's convention is expected to host over 9,000 companies from more than 90 countries, with more than 20,000 attendees anticipated. From Korea alone, over 100 companies are officially registered, and when including firms without booths that are attending for networking and business opportunities, the number of participating Korean firms is expected to reach around 400, reflecting the growing presence and ambition of K-bio on the global stage. Among the major Korean participants is Samsung Biologics, which is attending for the 13th consecutive year with its own booth. With a massive 167-square-meter booth at the center of the venue, Samsung plans to actively showcase its industry-leading biologics manufacturing capacity of 784,000 liters per year, as well as its newly launched ADC service, underlining its competitiveness as a CDMO. 'This year, we've designed an interactive booth featuring curved LED screens and touchscreen displays that allow visitors to explore our range of services while highlighting our strengths in digitalization,' said James Choi, executive vice president at Samsung Biologics. 'Through three touchscreen stations, we effectively present the core strengths and expertise of our research, development and manufacturing services.' Meanwhile, Samsung Biologics announced the launch of its new organoid-based drug screening platform, Samsung Organoids, marking an expansion into clinical research organization services. The service focuses on screening anti-cancer drug candidates using cancer patient-derived organoids, aiming to replace traditional cell and animal models. Celltrion, a Bio USA participant since 2010, is marking its 16th consecutive appearance with a 140-square-meter booth. It has prepared both open and private meeting spaces for discussions with multiple global partners. In addition to its well-established biosimilars, the company aims to expand collaboration around the next-generation ADCs and innovative antibody drugs in its pipeline. SK Biopharmaceuticals has set up its first-ever independent booth at the convention. 'This year, we have around 200 meetings scheduled, mostly related to licensing out and second-product discussions,' said an SK Biopharmaceuticals official. 'We're working to expand into oncology and other therapeutic areas and are especially focused on building partnerships in Europe.' The booth features a compelling video testimonial from multiple patients using Xcopri, its anti-epileptic drug, displayed on the main stage. With a strong track record in the US market since Xcopri's launch in 2020, surpassing 170,000 cumulative patients as of the first half of this year, SK is using this momentum to enhance its brand image and attract new partners. CHA Vaccine Institute, an affiliate of CHA Biotech, is exhibiting within the Korean pavilion, hosted by Korea Bio in partnership with KOTRA. The company is highlighting two vaccine candidates: its herpes zoster vaccine CVI-VZV-001 and hepatitis B vaccine CVI-HBV-002, focusing on technology licensing and co-development opportunities. 'Leveraging our proprietary adjuvant technology, we've scheduled meetings with around 20 potential partners and investors, mainly from Europe, the Middle East and South America,' said a CHA Vaccine Institute official. 'We'll present our R&D direction and market entry strategies for our shingles vaccine during investor relations sessions, aiming to attract more investors as a listed company.' Meanwhile, anticipation is high as Korea's biotech sector is on the verge of reaching 10 trillion won ($7.7 billion) in annual technology exports for the first time in four years, with over 7 trillion won already recorded this year. With such result, promising Korean drug developers are actively seeking new business opportunities at Bio USA. ABL Bio, known for its bispecific antibody technology — able to target two different antigens — aims to build on the momentum of its April deal with GSK worth up to 4.1 trillion won, centered on Grabody-B, a product that delivers drugs across the blood-brain barrier. AriBio, currently conducting a global Phase 3 trial for its oral Alzheimer's drug candidate AR1001, is also eyeing new partnerships. The company recently signed an 820-billion-won exclusive distribution agreement with Arcera, a subsidiary of UAE's sovereign wealth fund ADQ.
Korea Herald
01-05-2025
- Korea Herald
S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial
SEOUL, South Korea, May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b clinical trial of its investigational stroke therapy, SNE-101. This is the first exosome-based therapy in Korea to enter clinical trials, marking a major milestone in the country's biopharmaceutical landscape. S&E bio developed SNE-101 using a proprietary 3D culture system to optimize exosome production from umbilical cord-derived mesenchymal stem cells. The exosomes carry therapeutic microRNAs designed to enhance neuroregeneration. The approval followed successful resolution of Chemistry, Manufacturing, and Controls (CMC) issues, as well as demonstration of therapeutic efficacy not only in rodent models but also in non-human primates, which better reflect human stroke pathology. Long-term safety was also confirmed. The Phase 1b trial will evaluate the safety, dose-limiting toxicity, and preliminary efficacy of SNE-101 via intravenous administration. As no approved pharmacological therapies currently exist beyond reperfusion treatments for stroke, SNE-101's potential neuroregenerative, neuroprotective, and anti-inflammatory effects offer new hope for improving recovery in stroke patients. Media Contact:
